AUTHOR=Lahiri Durjoy , Seixas-Lima Bruna , Roncero Carlos , Verhoeff Nicolaas Paul , Freedman Morris , Al-Shamaa Sarmad , Chertkow Howard 

TITLE=CAPS: a simple clinical tool for β-amyloid positivity prediction in clinical Alzheimer syndrome

JOURNAL=Frontiers in Neurology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1422681

DOI=10.3389/fneur.2024.1422681

ISSN=1664-2295

ABSTRACT=<sec id="sec1"><title>Introduction</title><p>With the advent of anti-β-amyloid therapies, clinical distinction between Aβ + and Aβ− in cognitive impairment is becoming increasingly important for stratifying referral and better utilization of biomarker assays.</p></sec><sec id="sec2"><title>Methods</title><p>Cognitive profile, rate of decline, neuropsychiatric inventory questionnaire (NPI-Q), and imaging characteristics were collected from 52 subjects with possible/probable AD.</p></sec><sec id="sec3"><title>Results</title><p>Participants with Aβ+ status had lower baseline MMSE scores (24.50 vs. 26.85, <italic>p</italic> = 0.009) and higher total NPI-Q scores (2.73 vs. 1.18, <italic>p</italic> &lt; 0.001). NPI-Q score was found to be the only independent predictor for β-amyloid positivity (<italic>p</italic> = 0.008). A simple scoring system, namely Clinical β-Amyloid Positivity Prediction Score (CAPS), was developed by using the following parameters: NPI-Q, rapidity of cognitive decline, and white matter microangiopathy. Data from 48 participants were included in the analysis of accuracy of CAPS. CAP Score of 3 or 4 successfully classified Aβ + individuals in 86.7% cases.</p></sec><sec id="sec4"><title>Discussion</title><p>Clinical β-Amyloid Positivity Prediction Score is a simple clinical tool for use in primary care and memory clinic settings to predict β-amyloid positivity in individuals with clinical Alzheimer Syndrome can potentially facilitate referral for Anti Aβ therapies.</p></sec>